To confirm a reactive HCV screening result with confidence, a strip immunoblot assay (SIA/LIA) must combine a carefully selected set of recombinant proteins and synthetic peptides that span multiple viral regions. The recommended formulation includes recombinant antigens from the NS3 helicase region, NS4A, NS4B, NS5A, and NS5, paired with synthetic peptides representing the core region (c22), NS4 regions (5-1-1 and c100), and the hypervariable region (HVR) of the E2 envelope glycoprotein. This blend of structural and non-structural targets creates a robust check that resolves ambiguous screening results by capturing the full breadth of the anti-HCV antibody response.
A successful HCV supplementary strip immunoblot does not rely on a single marker. It confirms infection by requiring the patient’s antibodies to independently recognize multiple, unrelated viral epitopes—combining recombinant proteins from the NS3-to-NS5 non-structural complex with synthetic peptides from the core, NS4, and E2 regions turns a reactive screening signal into a definitive diagnosis.
Why a Multi-Antigen Strip Design Matters
Supplementary assays are not used for high-throughput screening. They serve as a referee, resolving false-positive results caused by non‑specific cross-reactivity. To do that, the strip must present a diverse panel of antigens that probe different parts of the viral proteome and different stages of the immune response.
Covering the Entire Proteome with Redundancy
A single antigen is vulnerable to both false negatives (missing infections that don’t elicit antibodies to that target) and false positives (capturing a non‑HCV antibody that happens to bind).
Recombinant non‑structural proteins like NS3, NS4A/B, and NS5A provide large, conformationally rich epitopes that are highly immunogenic across genotypes. Synthetic peptides such as c22 (core) and c100 (NS4) add precise linear B-cell epitopes that often drive the earliest antibody production. This redundancy ensures that if one region is missed due to viral strain variation or a weak individual response, other regions can still confirm infection.
Capturing Early and Late Immune Response Dynamics
The timing of antibody appearance varies dramatically. Anti‑NS3 and anti‑core antibodies can appear during seroconversion, while anti‑NS5 and anti‑NS4 antibodies may rise and persist later. By combining antigens from both the structural core and the entire non‑structural (NS3‑NS5) module, the strip remains sensitive from the window period through chronic infection. The inclusion of E2 HVR peptides addresses a unique niche—the hypervariable region of the envelope glycoprotein—where genotype-specific antibodies often emerge, adding coverage where other antigens may fail to react.
Ensuring Cross-Genotype Confirmation
HCV has seven major genotypes and many subtypes. While the NS3 helicase and core protein are relatively conserved, the NS4 and E2 regions exhibit substantial divergence.
Using recombinant NS3 helicase, NS4A, and NS5A provides broad cross‑genotype reactivity due to conserved functional domains. Complementing these with c100 (NS4) and 5‑1‑1 (NS4) synthetic peptides introduces genotype‑specific epitopes originally derived from genotype 1a, but their structural presentation often captures antibodies from related genotypes. The E2 HVR peptide further expands genotype coverage by targeting a region where even small sequence differences can be immunologically distinct—if the peptide panel includes multiple genotype representatives, it becomes a powerful tool to avoid false‑negative confirmations in non‑1 genotypes.
The Core Formulation: Recombinant and Synthetic Partners in Detail
The specific combination recommended is not arbitrary; it is a function of antibody kinetics, antigen stability, and the need to distinguish true anti‑HCV from interfering immunoglobulins.
Recombinant Antigens: The Backbone of Non‑Structural Confirmation
The non‑structural proteins are produced as full-length or domain‑specific recombinant polypeptides in expression systems that preserve native‑like folding.
- NS3 helicase region provides a highly immunogenic, conserved domain that frequently elicits a strong IgG response early in infection.
- NS4A, NS4B, and NS5A form a multi‑protein complex in vivo; including them as separate recombinant antigens prevents steric hindrance and allows each to present its unique epitopes, boosting overall sensitivity.
- NS5 (often the NS5B RNA polymerase region) serves as a late‑phase marker—positive NS5 reactivity strongly correlates with chronic, replicating infection and helps rule out resolved or passively acquired antibodies.
Synthetic Peptides: Precision Epitopes for Structural and Early Targets
Synthetic peptides offer advantages where recombinant full-length proteins may contain host‑cell impurities or where small linear epitopes drive the immune response.
- Core region c22 is one of the most consistently recognized epitopes during seroconversion. A synthetic peptide representing this region eliminates any risk of co‑purified E. coli proteins that could cause false reactivity.
- NS4 peptides 5‑1‑1 and c100 epitomize the classic confirmatory targets. These short sequences, when spotted as individual bands, provide highly specific binding—a positive signal to c100 and 5‑1‑1 together, alongside NS3, dramatically reduces the likelihood of a false‑positive confirmation.
- E2 HVR peptide addresses the envelope glycoprotein, which is often the target of neutralizing antibodies. Even though HVR is hypervariable, including a representative peptide—often from the predominant genotype in the target population—captures an additional class of antibodies that might otherwise be missed if only core and NS4 peptides are used.
Understanding the Trade-offs
No antigen formulation is perfect. Designing a successful strip requires deliberately balancing sensitivity against specificity.
Over‑reliance on core‑only peptides can increase false positives. The c22 epitope can cross‑react with antibodies induced by other flaviviruses or autoimmune conditions. Therefore, a positive strip must never be interpreted based on core reactivity alone; the inclusion of multiple non‑structural recombinant proteins serves as a critical specificity filter.
Recombinant proteins may contain E. coli contaminants. While synthetic peptides are highly pure, the recombinant NS3, NS4, and NS5 antigens are often expressed in bacterial systems. Anti‑E. coli antibodies present in some human sera can cause non‑specific binding. This is mitigated by including a negative control band and by using a strip setup where at least two distinct recombinant bands (e.g., NS3 and NS5A) must be positive to confirm, reducing the impact of single‑antigen contamination.
Broad coverage can dilute the interpretive clarity. Including many bands risks complicated scoring algorithms and potential indeterminate results if only one band reacts. The recommended combination must be used with a validated interpretation algorithm—usually requiring reactivity to at least two different viral gene products (e.g., one structural peptide and one non‑structural recombinant protein) for a confirmed positive result.
Making the Right Choice for Your Assay Design Goal
The right combination depends on your target population, local genotype prevalence, and your tolerance for indeterminate results. Use the following guidance to tailor your formulation:
- If your primary focus is maximum sensitivity for early seroconversion panels: Prioritize the inclusion of c22 core peptide and recombinant NS3 helicase, as these markers appear earliest and most consistently.
- If your primary focus is eliminating false positives in low‑prevalence settings: Strengthen the non‑structural component by ensuring clear reactivity to at least two separate recombinant antigens (NS3 and NS5A) and include NS4 synthetic peptides (c100/5‑1‑1) as an additional specificity check.
- If your primary focus is broad genotype coverage in a diverse population: Augment the E2 HVR peptide to include representatives from multiple genotypes (e.g., 1a, 1b, 3a) and verify that your recombinant NS3 and NS5A antigens react with all major genotypes through cross‑panel testing.
By combining recombinant NS3‑NS5 proteins with synthetic core, NS4, and E2 peptides, you build a supplementary strip assay that acts as a true diagnostic referee—confirming true infection while calmly dismissing the noise of non‑specific screening reactivity.
Summary Table:
| Antigen / Target | Type | Viral Region | Diagnostic Role & Value |
|---|---|---|---|
| NS3 Helicase | Recombinant Protein | Non-structural (NS3) | High immunogenicity; captures early IgG response across genotypes |
| NS4A, NS4B, NS5A | Recombinant Proteins | Non-structural (NS4/NS5) | Presented separately to prevent steric hindrance and ensure broad reactivity |
| NS5 (NS5B) | Recombinant Protein | Non-structural (NS5) | Late-phase marker; strongly correlates with chronic viral replication |
| Core (c22) | Synthetic Peptide | Structural (Core) | Precise linear epitope essential for detecting early seroconversion |
| NS4 (c100 & 5-1-1) | Synthetic Peptides | Non-structural (NS4) | Highly specific targets that minimize false-positive cross-reactivity |
| E2 HVR | Synthetic Peptide | Envelope (E2) | Targets hypervariable region to capture genotype-specific neutralizing antibodies |
Accelerate Your HCV Assay Development with CamelBio
Developing high-performance HCV confirmatory assays requires optimized antigen combinations and uncompromised raw material purity. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—covering every stage from concept to clinic.
Whether you are formulating a new strip immunoblot assay or refining an existing assay panel, our team is here to support your technical and supply chain needs. Contact CamelBio today to request product samples, technical documentation, or customized formulation consulting!